Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus. 2010

Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
Transplantation Laboratory, Cancer Gene Therapy Group, Molecular Cancer Biology Program, Haartman Institute, University of Helsinki, Helsinki, Finland. laura.ahtiainen@helsinki.fi

BACKGROUND Cancer stem cells/initiating cells (CSC/CIC), are thought to exist as a small population in malignant tissues. They are resistant to conventional cancer treatments and possibly underlie post-treatment relapse. The CIC population can be targeted with capsid modified oncolytic adenoviruses. RESULTS We studied the mechanisms of innate immunity to oncolytic adenovirus Ad5/3-Delta24 in conventional treatment resistant non-CIC breast cancer cells, breast cancer CD44(+)/CD24(-/low) CIC population and normal breast tissue CD44(+)/CD24(-/low) stem cells. We compared virus recognition by pattern recognition receptors for adenovirus, Toll-like receptors (TLR) 2 and 9 and virus induced type I interferon (IFN) response regulation in these cell types. We show TLR mediated virus recognition in these non-immune cell types. Normal tissue stem cells have intact type I IFN signaling. Furthermore, TLR9 and TLR2 reside constantly in recognition sites, implying constant activation. In contrast, breast cancer CD44(+)/CD24(-/low) CIC have dysregulated innate immune responses featuring dysfunctional virus recognition caused by impaired trafficking of TLR9 and cofactor MyD88 and the absence of TLR2, having a deleterious impact on TLR pattern recognition receptor signaling. Furthermore, the CIC have increased inhibitory signaling via the suppressor of cytokine signaling/Tyro3/Axl/Mer receptor tyrosine kinase (SOCS/TAM) pathway. These defects in contribute to dysfunctional induction of type I IFN response in CIC and therefore permissivity to oncolytic adenovirus. CONCLUSIONS CICs may underlie the incurable nature of relapsed or metastatic cancers and are therefore an important target regarding diagnostic and prognostic aspects as well as treatment of the disease. This study addresses the mechanisms of innate infection immunity in stem cells deepening the understanding of stem cell biology and may benefit not only virotherapy but also immunotherapy in general.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008164 Luminescent Proteins Proteins which are involved in the phenomenon of light emission in living systems. Included are the "enzymatic" and "non-enzymatic" types of system with or without the presence of oxygen or co-factors. Bioluminescent Protein,Bioluminescent Proteins,Luminescent Protein,Photoprotein,Photoproteins,Protein, Bioluminescent,Protein, Luminescent,Proteins, Bioluminescent,Proteins, Luminescent
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000256 Adenoviridae A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases. Adenoviruses,Ichtadenovirus,Adenovirus,Ichtadenoviruses
D014411 Neoplastic Stem Cells Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS. Cancer Stem Cells,Colony-Forming Units, Neoplastic,Stem Cells, Neoplastic,Tumor Stem Cells,Neoplastic Colony-Forming Units,Tumor Initiating Cells,Cancer Stem Cell,Cell, Cancer Stem,Cell, Neoplastic Stem,Cell, Tumor Initiating,Cell, Tumor Stem,Cells, Cancer Stem,Cells, Neoplastic Stem,Cells, Tumor Initiating,Cells, Tumor Stem,Colony Forming Units, Neoplastic,Colony-Forming Unit, Neoplastic,Initiating Cell, Tumor,Initiating Cells, Tumor,Neoplastic Colony Forming Units,Neoplastic Colony-Forming Unit,Neoplastic Stem Cell,Stem Cell, Cancer,Stem Cell, Neoplastic,Stem Cell, Tumor,Stem Cells, Cancer,Stem Cells, Tumor,Tumor Initiating Cell,Tumor Stem Cell,Unit, Neoplastic Colony-Forming,Units, Neoplastic Colony-Forming
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings

Related Publications

Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
April 2014, Human gene therapy,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
December 2007, Molecular therapy : the journal of the American Society of Gene Therapy,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
February 2016, Molecular therapy : the journal of the American Society of Gene Therapy,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
October 2009, Molecular therapy : the journal of the American Society of Gene Therapy,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
May 2015, Cell death & disease,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
July 2019, Microorganisms,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
June 2016, Retrovirology,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
April 2024, Viruses,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
December 2019, FEBS letters,
Laura Ahtiainen, and Cristina Mirantes, and Tiina Jahkola, and Sophie Escutenaire, and Iulia Diaconu, and Pamela Osterlund, and Anna Kanerva, and Vincenzo Cerullo, and Akseli Hemminki
February 2021, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Copied contents to your clipboard!